Scarica l'app Stockscreener
21.16
2.32%
0.48
Dopo l'orario di chiusura:
21.00
-0.16
-0.76%
Precedente Chiudi:
$20.68
Aprire:
$20.11
Volume 24 ore:
1.56M
Relative Volume:
0.52
Capitalizzazione di mercato:
$1.33B
Reddito:
$16.10M
Utile/perdita netta:
$-198.97M
Rapporto P/E:
-6.0789
EPS:
-3.4809
Flusso di cassa netto:
$-183.99M
1 W Prestazione:
+17.23%
1M Prestazione:
+23.31%
6M Prestazione:
-18.80%
1 anno Prestazione:
+33.17%
Intervallo 1D:
$19.76
$21.27
Intervallo di 1 settimana:
$16.60
$21.27
Portata 52W:
$8.73
$71.50
Uniqure Nv Stock (QURE) Company Profile
Nome
Uniqure Nv
Settore
Industria
Telefono
1-339-970-7000
Indirizzo
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure Nv
|
21.16 | 1.30B | 16.10M | -198.97M | -183.99M | -3.4809 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Uniqure Nv Stock (QURE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-11 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2026-03-09 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-03-09 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2026-03-03 | Downgrade | Mizuho | Outperform → Neutral |
| 2026-03-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2026-03-02 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2026-03-02 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-02-24 | Iniziato | Wolfe Research | Peer Perform |
| 2026-01-28 | Iniziato | Barclays | Equal Weight |
| 2025-11-04 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-08-14 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2025-04-01 | Ripresa | Chardan Capital Markets | Buy |
| 2024-12-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-02-29 | Downgrade | Goldman | Buy → Neutral |
| 2023-12-19 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-17 | Aggiornamento | UBS | Neutral → Buy |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-05-21 | Iniziato | UBS | Neutral |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-04-01 | Aggiornamento | Mizuho | Neutral → Buy |
| 2021-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-24 | Iniziato | H.C. Wainwright | Buy |
| 2020-11-11 | Iniziato | Berenberg | Buy |
| 2020-11-09 | Iniziato | Jefferies | Buy |
| 2020-11-04 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-08-25 | Iniziato | Raymond James | Strong Buy |
| 2020-07-31 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | Downgrade | Mizuho | Buy → Neutral |
| 2020-06-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | Iniziato | Cowen | Outperform |
| 2019-12-03 | Iniziato | Goldman | Buy |
| 2019-11-05 | Iniziato | Credit Suisse | Outperform |
| 2019-10-11 | Iniziato | Stifel | Buy |
| 2019-09-25 | Iniziato | Bernstein | Outperform |
| 2019-09-12 | Iniziato | Mizuho | Buy |
| 2019-07-30 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-07-08 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-04-12 | Iniziato | Piper Jaffray | Overweight |
| 2019-03-29 | Iniziato | Robert W. Baird | Outperform |
Mostra tutto
Uniqure Nv Borsa (QURE) Ultime notizie
Uniqure NV at TD Cowen Healthcare Conference Transcript - GuruFocus
uniQure Q1 Earnings Call Highlights - Yahoo Finance
Stifel Maintains UniQure NV(QURE.US) With Buy Rating, Announces Target Price $28 - Moomoo
UniQure N.V. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
UniQure Shares Fall After Q1 Loss Widens - marketscreener.com
uniQure Releases Q1 2026 Financial Results - AlphaStreet
Transcript: uniQure Q1 2026 Earnings Conference Call - Benzinga
Uniqure NV reports results for the quarter ended March 31Earnings Summary - TradingView
uniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Earnings Flash (QURE) UniQure Posts Q1 Net Loss $0.85 a Share, vs. FactSet Est of $0.85 Loss - marketscreener.com
Earnings Flash (QURE) uniQure N.V. Reports Q1 Revenue $3.6M, vs. FactSet Est of $5.2M - marketscreener.com
uniQure N.V. 1Q 2026: Revenue $3.56M, Net income ($53.54M), EPS ($0.85) — 10-Q Summary - TradingView
[10-Q] uniQure N.V. Quarterly Earnings Report - Stock Titan
uniQure targets UK filing for AMT-130 as FDA seeks new trial plan - Stock Titan
uniQure (NASDAQ: QURE) Q1 2026 loss widens, holds $586.6M cash runway - Stock Titan
uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates - Yahoo Finance
MSN Money - MSN
uniQure’s AMT-130 Regulatory Progress Sharpens Huntington’s Disease Investment Case - Yahoo Finance
US-listed shares of uniQure NV rise nearly 20% - marketscreener.com
UniQure plummets as FDA calls for phase 3 trial for Huntington's asset AMT-130 - MSN
Jennison Associates LLC Boosts Stake in uniQure N.V. $QURE - MarketBeat
uniQure advances AMT-130 toward UK marketing approval - The Globe and Mail
Update: UniQure Shares Rise After Firm Plans to Submit UK Marketing Application for Huntington's Disease Treatment - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
uniQure (QURE) Shares Surge 22% on Positive Regulatory News for AMT-130 - GuruFocus
uniQure NV | SCHEDULE 13G/A: Others - Moomoo
UniQure Plans to Submit UK Marketing Authorization Application for Huntington's Disease Treatment - Moomoo
uniQure stock rises after regulatory updates (QURE:NASDAQ) - Seeking Alpha
UniQure, in ‘symbolic’ win, to seek UK approval of Huntington’s gene therapy - BioPharma Dive
uniQure (NASDAQ:QURE) Shares Gap UpHere's Why - MarketBeat
uniQure plans UK filing for Huntington’s gene therapy AMT-130 By Investing.com - Investing.com India
QURE Stock Just Shot Up 8%uniQure’s Much-Talked-About Huntington’s Disease Therapy Gets A UK Boost - Stocktwits
uniQure meets with UK MHRA on AMT-130 for Huntington’s disease - The Pharma Letter
Aberdeen Group (QURE) reports 5.31M shares, 8.49% stake | Schedule 13G/A - Stock Titan
uniQure plans UK filing for Huntington’s gene therapy AMT-130 - Investing.com
uniQure NV | 8-K: Current report - Moomoo
AMT-130 Huntington’s gene therapy nears UK filing for uniQure (NASDAQ: QURE) - Stock Titan
uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington’s Disease - Yahoo Finance
Earnings Preview: UniQure NV to Report Financial Results Pre-market on May 05 - 富途牛牛
QURE stock crashes 32% in a week: Here's what you should know - MSN
H.C. Wainwright Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $70 - Moomoo
uniQure N.V. (NASDAQ:QURE) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
UniQure used 'distorted comparison' in Huntington's asset trial: FDA official - MSN
UniQure surges following departure of key FDA official - MSN
UniQure to Announce First Quarter 2026 Financial Results - marketscreener.com
uniQure to Announce First Quarter 2026 Financial Results - Sahm
uniQure NV (MEX:QUREN) Stock Earnings Transcripts - GuruFocus
uniQure NV | DEF 14A: Definitive information statements - Moomoo
uniQure NV | ARS: Annual Report to Security Holders - Moomoo
uniQure (NASDAQ: QURE) outlines 2026 proxy agenda, equity and charter changes - Stock Titan
[ARS] uniQure N.V. SEC Filing - Stock Titan
Uniqure Nv Azioni (QURE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):